SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two Phase III trials. J Clin Oncol. 1996; 14: 20002011.
  • 2
    Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex®), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer. 1996; 74: 12861291.
  • 3
    Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol. 1998; 9: 639645.
  • 4
    Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991; 51: 38673873.
  • 5
    Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer. 2000; 7: 1728.
  • 6
    Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5 (10)-triene-3,17betadiol (Faslodex™) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001; 61: 67396746.
  • 7
    DeFriend DJ, Anderson E, Bell J, et al. Effects of 4-hydroxytamoxifen and a novel pure antiestrogen (ICI 182,780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer. 1994; 70: 204211.
  • 8
    Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995; 87: 746750.
  • 9
    DeFriend DJ, Howell A, Nicholson RI, et al. Investigation of a new pure antiestrogen (ICI 182,780) in women with primary breast cancer. Cancer Res. 1994; 54: 408414.
  • 10
    Howell A, DeFriend D, Robertson J, Blamey R, Walton P. Response to a specific antiestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet. 1995; 345: 2930.
  • 11
    Howell A, DeFriend DJ, Robertson JF, et al. Pharmacokinetics, pharmacological, and anti-tumour effects of the specific anti-oestrogen ICI 182,780 in women with advanced breast cancer. Br J Cancer. 1996; 74: 300308.
  • 12
    Robertson JF, Blamey RW, Howell A, Anderson L, DeFriend D, Walton P. Duration of response to ICI 182,780 appears significantly longer than “Megace” in tamoxifen-resistant breast cancer [abstract]. Breast Cancer Res Treat. 1996; 37 (Suppl): 33.
  • 13
    Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002; 20: 33963403.
  • 14
    Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002; 20: 33863395.
  • 15
    Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. A project of the Programme on Clinical Oncology of the International Union against Cancer, Geneva, Switzerland. Cancer. 1977; 39: 12891294.
  • 16
    Robertson JF. A comparison of the single-dose pharmacokinetics of ICI 182,780 (“Faslodex”) 250 mg when given as either a one × 5-ml intra-muscular injection or two × 2.5-mL injections in postmenopausal women with advanced breast cancer [abstract]. Breast Cancer Res Treat. 2000; 64: 53.
  • 17
    Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex™) development of a novel “pure” antiestrogen. Cancer. 2000; 89: 817825.
  • 18
    Brown RE, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics. 2001; 19: 10911102.
  • 19
    Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998; 16: 453461.
  • 20
    Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol. 2000; 18: 13991411.
  • 21
    Donnellan PP, Douglas SL, Cameron DA, Leonard RC. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001; 19: 2767.
  • 22
    Goss PE, Winer EP, Tannock IF, Schwartz LH. Randomized Phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. J Clin Oncol. 1999; 17: 5263.